I am a young adult with years of intermittent gastro‑esophageal reflux, excessive belching, bloating, nocturnal regurgitation and constipation that worsen after high‑fat or heavily grilled meals and after reducing caffeine, but improve with stimulant lisdexamfetamine (Vyvanse); what is the likely diagnosis and how should I manage it?

Likely Diagnosis: Gastroesophageal Reflux Disease with Delayed Gastric Emptying and Possible Supragastric Belching

You most likely have gastroesophageal reflux disease (GERD) complicated by delayed gastric emptying, with your excessive belching representing a behavioral component (supragastric belching) that developed secondary to chronic reflux. The dramatic improvement with stimulant medications (caffeine and Vyvanse) strongly suggests that impaired gastric motility is a central driver of your symptoms, as these agents accelerate gastric emptying and enhance esophageal clearance. 1, 2

Understanding Your Symptom Pattern

Your clinical course reveals three distinct phases that point to a motility-driven GERD phenotype:

• Phase 1 (2018–2019): Excessive belching triggered by high-fat barbecued foods lasting 3–7 days suggests delayed gastric emptying of fatty meals, with the belching likely representing both physiologic venting of gastric air and learned supragastric belching behavior that developed as a compensatory response. 3, 4

• Phase 2 (High caffeine intake): When consuming 3–7 espresso shots daily, your symptoms largely resolved because caffeine acts as a prokinetic agent, accelerating gastric emptying and reducing the substrate available for reflux. 1, 2

• Phase 3 (Caffeine withdrawal): Abrupt reduction in caffeine unmasked severe GERD with nocturnal regurgitation and vomiting of undigested food—classic signs of gastroparesis or severe gastric stasis—requiring 4–5 hours upright after eating before you could safely lie down. 1, 2

• Phase 4 (Vyvanse era): Lisdexamfetamine, a sympathomimetic stimulant, mimics caffeine's prokinetic effects by enhancing gastric motility and esophageal clearance, again controlling your symptoms. 1, 2

The constipation noted on your 2023 X-ray further supports a generalized motility disorder affecting the entire gastrointestinal tract. 1

Immediate Management Strategy

Step 1: Optimize Acid Suppression

• Start omeprazole 20 mg taken 30–60 minutes before breakfast for 4 weeks. If symptoms persist, escalate to twice-daily dosing (one dose before breakfast, one before dinner) for an additional 4–8 weeks. 2, 5

• Do not add a bedtime H₂-receptor antagonist to twice-daily PPI therapy; this combination provides no additional benefit and tachyphylaxis develops within 6 weeks. 2

Step 2: Address Gastric Motility

• Reintroduce a modest daily caffeine intake (1–2 cups of coffee or 1–2 espresso shots) in the morning to leverage its prokinetic effect on gastric emptying. 1, 2

• Continue your current Vyvanse regimen as prescribed by your physician, since it clearly provides motility benefit and symptom control. 1, 2

• Avoid metoclopramide despite its prokinetic properties, because the risk of tardive dyskinesia and extrapyramidal side effects outweighs any benefit in GERD management. 2, 6

Step 3: Implement Critical Lifestyle Modifications

• Elevate the head of your bed by 6–8 inches using sturdy blocks or a wedge (not pillows alone) to reduce nocturnal acid exposure and prevent regurgitation. 2, 5, 7

• Avoid lying down for 3 hours after meals to allow adequate gastric emptying before assuming a supine position. 2, 5, 7

• Limit dietary fat to ≤45 grams per day, because high-fat meals (especially barbecued foods with added oils and fatty meats) delay gastric emptying and prolong reflux exposure. 2, 7

• Eat 5–6 smaller meals throughout the day rather than 3 large meals, to reduce gastric distension and reflux episodes. 7

• If you are overweight (BMI ≥25 kg/m²), prioritize weight loss—this is the single most effective lifestyle intervention for GERD, with Grade B evidence showing improved esophageal pH profiles and symptom reduction. 2, 5

Step 4: Manage Excessive Belching

• Recognize that your belching likely includes a supragastric component: the air is being sucked into the esophagus from the pharynx and immediately expelled, rather than originating from the stomach. This behavior often develops unconsciously in response to reflux discomfort. 4

• Consider referral to a speech therapist or behavioral psychologist trained in diaphragmatic breathing exercises to extinguish the supragastric belching habit. 1, 4

• Avoid carbonated beverages, chewing gum, and eating rapidly, as these behaviors increase aerophagia and exacerbate belching. 3, 4

Diagnostic Evaluation Timeline

At 8–12 Weeks

• If symptoms remain uncontrolled after 8–12 weeks of optimized twice-daily PPI therapy plus lifestyle measures, schedule upper endoscopy to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett's esophagus, strictures, or alternative diagnoses such as eosinophilic esophagitis. 1, 2

• If endoscopy is normal but symptoms persist, perform 24-hour pH-impedance monitoring off PPI (withhold therapy for 2–4 weeks) to confirm pathological acid exposure, detect non-acid reflux, and establish a symptom-reflux correlation. 1, 2

• Consider gastric-emptying scintigraphy if vomiting of undigested food recurs or if you cannot tolerate lying down within 4–5 hours of eating, to objectively document gastroparesis. 1

High-Resolution Esophageal Manometry

• Obtain manometry before any consideration of anti-reflux surgery to exclude achalasia, assess esophageal peristaltic function, and identify ineffective esophageal motility that would favor partial (rather than complete) fundoplication. 1, 2

Long-Term Management

Maintenance Acid Suppression

• Once symptom control is achieved, taper PPI to the lowest effective dose that maintains relief. 2, 5

• If endoscopy documents erosive esophagitis (Los Angeles B or higher) or Barrett's esophagus, continue at least single-dose daily PPI indefinitely to prevent recurrence and complications. 1, 2

• If endoscopy is normal and you have no erosive disease, consider on-demand PPI therapy once symptoms are stable for several months. 2

Addressing Constipation

• Increase dietary fiber intake to 25–30 grams daily and ensure adequate hydration (≥2 liters of water per day) to improve colonic transit. 1

• If constipation persists, consider polyethylene glycol 3350 (17 grams daily) as a safe, non-stimulant osmotic laxative. 1

Surgical Consideration

• Anti-reflux surgery (laparoscopic fundoplication) is appropriate only if you meet all of the following criteria:

  1. Failure of ≥3 months of intensive medical therapy (twice-daily PPI + prokinetic strategy + lifestyle measures).
  2. Objective documentation of pathological GERD (erosive esophagitis on endoscopy or abnormal pH monitoring off PPI).
  3. Positive symptom-reflux correlation on pH-impedance testing.
  4. Preserved esophageal peristalsis on high-resolution manometry.
  5. Significant impairment of quality of life despite maximal medical therapy. 1, 2

• If ineffective esophageal motility is present on manometry, partial fundoplication (Toupet or Dor) is preferred over complete (Nissen) fundoplication to reduce the risk of postoperative dysphagia. 1, 2

Critical Pitfalls to Avoid

• Do not discontinue Vyvanse without consulting your prescribing physician, as your symptom improvement with this medication suggests it is providing essential prokinetic benefit beyond its primary indication. 1, 2

• Do not continue empiric PPI therapy indefinitely without objective testing if symptoms persist beyond 3 months of optimized treatment; endoscopy and pH monitoring are required to confirm GERD and guide long-term management. 1, 2

• Do not assume that normal endoscopy rules out GERD; up to 60% of patients with PPI-refractory symptoms have non-erosive reflux disease or esophageal hypersensitivity that requires pH-impedance testing for diagnosis. 1, 2

• Do not ignore the behavioral component of your belching; supragastric belching will not respond to acid suppression or prokinetics alone and requires targeted behavioral intervention. 4